# Docetaxel in Non Small Cell Lung Cancer (NSCLC)

> **NCT00258739** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 140 (actual)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine
- **OTHER:** Docetaxel + gemcitabine + carboplatin + radiotherapy

## Key facts

- **NCT ID:** NCT00258739
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2009-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258739, "Docetaxel in Non Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00258739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*